162 related articles for article (PubMed ID: 18071861)
1. Hormonal therapy.
Namiki M; Ueno S; Kitagawa Y; Konaka H; Mizokami A; Koh E; Fukagai T
Int J Clin Oncol; 2007 Dec; 12(6):427-32. PubMed ID: 18071861
[TBL] [Abstract][Full Text] [Related]
2. Primary combined androgen blockade in localized disease and its mechanism.
Namiki M; Kitagawa Y; Mizokami A; Koh E
Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):303-15. PubMed ID: 18471788
[TBL] [Abstract][Full Text] [Related]
3. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
6. National practice patterns and time trends in androgen ablation for localized prostate cancer.
Cooperberg MR; Grossfeld GD; Lubeck DP; Carroll PR
J Natl Cancer Inst; 2003 Jul; 95(13):981-9. PubMed ID: 12837834
[TBL] [Abstract][Full Text] [Related]
7. Survival following primary androgen deprivation therapy among men with localized prostate cancer.
Lu-Yao GL; Albertsen PC; Moore DF; Shih W; Lin Y; DiPaola RS; Yao SL
JAMA; 2008 Jul; 300(2):173-81. PubMed ID: 18612114
[TBL] [Abstract][Full Text] [Related]
8. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective.
Akaza H
Cancer Sci; 2006 Apr; 97(4):243-7. PubMed ID: 16630114
[TBL] [Abstract][Full Text] [Related]
9. Age at diagnosis on prostate cancer survival undergoing androgen deprivation therapy as primary treatment in daily practice: results from Japanese observational cohort.
Inamoto T; Azuma H; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Kazuhiro S; Naito S; Namiki M; Nishimura K; Hirao Y; Usami M; Murai M; Akaza H;
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1197-204. PubMed ID: 24676427
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of primary androgen-deprivation therapy for clinically localized prostate cancer.
Potosky AL; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Jiang M; Tsai HT; Luta G; Keating NL; Smith MR; Van Den Eeden SK
J Clin Oncol; 2014 May; 32(13):1324-30. PubMed ID: 24638009
[TBL] [Abstract][Full Text] [Related]
11. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
12. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a Japanese perspective--the effect of primary androgen deprivation therapy on stage C prostate cancer.
Akaza H
BJU Int; 2007 Jan; 99 Suppl 1():10-2; discussion 17-8. PubMed ID: 17229161
[TBL] [Abstract][Full Text] [Related]
13. Primary Androgen-Depletion Therapy Prevails Not Only for Metastatic but Also for Nonmetastatic Hormone-Naïve Prostate Cancer in Japan-Recent Trends and Efficacy.
Onozawa M; Hinotsu S; Saito A; Uno S; Akaza H
Gan To Kagaku Ryoho; 2021 Jul; 48(7):911-919. PubMed ID: 34267028
[TBL] [Abstract][Full Text] [Related]
14. Medical therapy of prostate cancer. A review.
Roscigno M; Sangalli M; Mazzoccoli B; Scattoni V; Da Pozzo L; Rigatti P
Minerva Urol Nefrol; 2005 Jun; 57(2):71-84. PubMed ID: 15951731
[TBL] [Abstract][Full Text] [Related]
15. Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.
Cooperberg MR; Hinotsu S; Namiki M; Carroll PR; Akaza H
BJU Int; 2016 Jan; 117(1):102-9. PubMed ID: 25238114
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy.
Cooperberg MR; Hinotsu S; Namiki M; Ito K; Broering J; Carroll PR; Akaza H
J Clin Oncol; 2009 Sep; 27(26):4306-13. PubMed ID: 19667269
[TBL] [Abstract][Full Text] [Related]
18. Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.
Akaza H
Pharmacology; 2010; 85(2):110-20. PubMed ID: 20130444
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer: primary ADT monotherapy not suitable for localized disease.
Sartor O; Silberstein J
Nat Rev Urol; 2014 Jun; 11(6):309-10. PubMed ID: 24861329
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
Sciarra A; Abrahamsson PA; Brausi M; Galsky M; Mottet N; Sartor O; Tammela TL; Calais da Silva F
Eur Urol; 2013 Nov; 64(5):722-30. PubMed ID: 23628492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]